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In recent decades, research in the 
biomedical sciences has been increasingly 
located in settings outside of the global 
north (Petryna 2009). Much of this research 
arises out of transnational collaborations 
made up of sponsors in richer countries 
(pharmaceutical industries, aid agencies, 
charitable trusts) and researchers and 
research subjects in poorer ones. A recent 
workshop on the ethics of international 
collaboration, held in Sri Lanka1, confi rmed 
that in addition to the usual concerns 
about the protection of human subjects in 
biomedical research, these engagements 
raise a host of new ones.  
Robert Simpson
RESEARCH MAY WELL BE CARRIED OUT in populations rendered vulnerable because 
of their low levels of education and literacy, poverty and limited access to health care. 
The protections that medical and research ethics off er in these contexts tend to be 
modelled on a western tradition in which individual, informed consent is paramount 
and, furthermore, is couched in legal and technical requirements. When science 
travels, so does its ethics. Yet, when cast against a wider backdrop of global health, 
economic inequalities and cultural diversity, such models often prove limited in eff ect 
and inadequate in their scope (Benatar 2002, Bhutta 2002). Attempts to address both 
of these concerns have generated a wide range of ‘capacity-building’ initiatives in 
bioethics in developing and transitional countries. Organisations such as the Global 
Forum for Bioethics in Research, the Forum for Ethical Review Committees in the Asia 
Pacifi c Region and the World Health Organisation have sought to improve oversight of 
research projects, refi ne regulation and guidance, address cultural variation, educate 
publics about research and strengthen ethical review committee structures according 
to internationally acknowledged ‘benchmarks’ (see for example, Emanuel et al 2004, 
Lavery et al 2007). They are also an essential pre-requisite when it comes to attract-
ing and hosting future collaborations, whether these are commercially sponsored, 
humanitarian or complex hybrids of the two.  
Bioethical capacity building
As part of a larger study of the ethics of international collaborations in biomedical 
research, our own work is focused on the ways in which a heightened pre-occupation 
with the ethics of research is playing out in contemporary Sri Lanka. Our aim is to 
map and to understand both the spread of international collaborative research as well 
as the intellectual, bureaucratic and political activity that is stimulated in the name of 
bioethics capacity building. However, in studying collaboration, we ourselves are also 
drawn into collaborations of various kinds. In this article we report on an event which 
was held to facilitate dialogue between ourselves and regional stakeholders in our 
research.2 The event focused on the ethics of international collaboration and provided 
an important context for refl ection on the current state of play and an opportunity 
to air some of the issues that are faced when it comes to national and regional 
engagement with global science and experimentation.
At one level, the workshop provided an opportunity for participants to show the 
considerable progress made in responding to the ethical challenges posed by the 
growing traffi  c in international collaboration and particularly where these concern 
the outsourcing of phase II and III clinical trials.  Signifi cantly, many of the discussions 
gravitated towards ethical review committees: their constitution, operation, remit 
and eff ectiveness. In conformity with the Declaration of Helsinki, such advisory 
groups are seen as crucial when it comes to anticipating the costs and benefi ts to 
those who are to be enrolled into biomedical research projects. Here, continuities 
with ethical review as a global bureaucratic form were clearly in evidence: reference 
to international protocols, membership of trans-national fora and operation within 
standard guidelines. However, what became apparent in discussions throughout 
the day was the diffi  culty that participants had in stabilising this form in practice. 
The fi eld of international biomedical research is changing extremely quickly, as are 
the mechanisms that are put in place to regulate and ensure protection of subjects. 
The eff ect of this would seem to leave the work of ethical review in a state of 
perpetual insuffi  ciency: an ever-widening remit, not 
enough committees, not enough scrutiny, not enough 
trained people and not enough public participation. 
Anxieties were expressed that shortcomings in ethical 
review could bring charges of being ‘unethical’ due to 
‘incompetence’. Such anxieties are greatly exacerbated 
when operating in settings where inequalities of risk are 
high, for example, because of poor education and literacy 
on the part of subjects and where negligence, corruption 
and exploitation are made possible by paternalistic and 
poorly regulated medical systems.  
Where external audiences are concerned, there is anxiety 
that such charges might be indexed to estimations of national 
development and scientifi c credibility. Apart from feeding 
unwelcome national stereotypes, appearing inadequate 
when it comes to the conduct of ethical review could have 
real consequences when it comes to the ability to attract 
research to the region, be this researcher-led research 
(funded by universities, charities, NGOs or governments) 
or sponsor-led research (funded by pharmaceutical companies). 
Where internal audiences are looking on, a diff erent set of 
anxieties present themselves. Discussion of contentious cases 
suggested that the committees fi nd themselves walking a fi ne 
line. On the one hand, they may be perceived as too restrictive, 
that is, unreasonably protective of human subjects and their 
interests and therefore impeding scientifi c and economic 
development. On the other hand, the expectation that ethics 
committees will operate as a kind of bulwark against moral 
and scientifi c imperialism might bring charges of excessive 
permissiveness, that is, they are not nearly protective enough 
of subjects and therefore are complicit in abuse, injustice or 
exploitation in research. Members can easily fi nd themselves 
vilifi ed from all sides. In this regard, an important question 
that emerged from the discussions is what happens when 
things go wrong following positive approval by an ethics 
committee and how to manage the professional and, 
possibly, legal ruptures that this brings. 
Ethical vanishing points?
The way to prevent ‘unethical’ process and outcome in 
the ethical review of research that was proff ered by many 
of the participants was further resort to ‘capacity-building’. 
Yet, it was hard to see that this strategy would not result 
in a remorseless game of catch-up into which all are drawn in 
the quest for some kind of ethical vanishing point. Indeed, as 
the discussions progressed, the load that ethical review was 
taking on seemed to get heavier and heavier, and, 
as a consequence, focus fell more on operating procedures 
and the way that these might be tightened up to ensure 
eff ective regulation of research. The momentum appeared 
to be moving fi rmly in the direction of greater procedural 
elaboration, more formulaic approaches to evaluation 
and a consequent consolidation of power in the process 
of ethical review, as national ethics cultures expand to fi ll 
the ambiguous moral spaces that international research 
increasingly opens up.
On the evidence of the collaborative workshop, the list of 
competences and responsibilities that ethics committees 
active in the fi eld of international collaboration might be 
expected to have is a long one.  They must cover relevance 
of the trial design, its scientifi c validity, the balance of risks and 
benefi ts, the suitability of investigators and the appropriate-
ness of informed consent procedures. Furthermore, the list is 
expanding as ethics committees strive to discharge their duties 
responsibly and embrace new dimensions of what it is to be 
‘ethical’. Here committees must, perforce, move into complex 
cultural territories for which there is little in the way 
of guidance. Examples alluded to included information sheets, 
the technicalities of translating informed consent documenta-
tion, insurance and compensation arrangements and the 
complex entanglement of voluntarism and commerce that 
runs through questions of payment to research participants. 
The waters were further muddied as participants grappled 
with ‘social benefi t’ or assessing the extent that certain kinds 
of research might result in ‘ethnic disharmony’. There was little 
evidence that the participants were in anyway shying away from 
the challenges that engaging with this agenda carries despite the 
considerable investment needed in terms of knowledge, time 
and resources. However, it was clear from the discussions on 
this particular occasion that those who are most centrally 
involved in conducting ethical review, see themselves as carrying 
enormous and, on occasion, impossible responsibilities and 
expectations. The task of making appear stable and authoritative 
that which is constantly evolving is a signifi cant one. For these 
reasons, the emergence and consolidation of ethical review in 
developing world contexts is an increasingly important site in 
which to study the transactions in knowledge, resources and 
fi nance that currently constitute international collaboration 
in biomedical research.
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Notes
1. The International Science and Bioethics Collaboration is 
funded by the UK’s Economic and Social Research Council  [RES 
062 23 0215] and is a collaboration between the Universities of 
Durham, Cambridge and Sussex.
2. The workshop took place in March 2009 in Colombo and 
was co-organised by three researchers from Durham University 
along with staff  of the Faculty of Medicine of the University 
of Colombo (specifi cally the Human Genetics Unit and the 
Faculty’s Ethics Review Committee). The theme for the day 
was the ethics of international collaboration. Case studies of 
international collaboration were presented by  Prof. Harun 
Ar-Rashid (Director, Bangladesh Medical Research Council), Dr. 
Vasantha Muthuswamy (MD, DGO. Former Deputy Director 
General, Indian Council for Medical Research), Dr. Shri Krishna 
Giri (Secretary, Nepal Health Research Council), Prof. Hemantha 
Senanayake (Chair of the Ethics Review Committee, Faculty of 
Medicine, University of Colombo, Sri Lanka). Dr. Cristina Torres 
(Co-ordinator, Forum for Ethical Review Committees in the Asia 
Pacifi c Region) gave an overview of the challenges faced in 
developing ethical review capacity in the region. The audience 
consisted mostly of local academics, doctors and clinical 
researchers.
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